Airoldi M, Bumma C, Cortesina G, Giordano C, Bussi M, Orecchia R, Succo G, Gabriele P, Bertetto O
Divisione di Oncologia Medica, Ospedale Oncologico S. Giovanni, Antica Sede, Torino.
Acta Otorhinolaryngol Ital. 1994 Nov-Dec;14(6):603-9.
Eighty-one patients with recurrent squamous cell carcinoma of the head and neck (60 patients) or undifferentiated carcinoma of the nasopharyngeal type (21 patients) were treated with cisplatin (80-100 mg/m2iv d1) and 5-fluorouracil (750-1000 mg/m2Cl d1-5). In squamous cell carcinoma patients there were 7 complete responses (11.6%), 25 partial responses (41.7%), 20 stable disease situations (33.3%) and 8 progressions (13.3%). In nasopharyngeal carcinoma patients there were 6 complete responses (28.6%), 9 partial responses (42.8%), 3 stable disease situations (14.3%) and 3 progression (14.3%). There were 5/60 patients (8.3%) with disease-free survival > 18 months in the squamous cell carcinoma group and 2/21 (9%) in the nasopharyngeal carcinoma group. All long-term survival patients had the following characteristics: good performance status (0-1 ECOG scale), disease- free interval from the first treatment > 12 months, local non-bulky relapse (rT1-2). A re-irradiation with palliative doses (20-48 Gy) was conducted in 3/7 patients. This treatment may have improved the response to drugs with regard to length and quality.
81例复发性头颈部鳞状细胞癌患者(60例)或鼻咽型未分化癌患者(21例)接受了顺铂(80 - 100mg/m²静脉滴注,第1天)和5-氟尿嘧啶(750 - 1000mg/m²持续静脉滴注,第1 - 5天)治疗。在鳞状细胞癌患者中,有7例完全缓解(11.6%),25例部分缓解(41.7%),20例病情稳定(33.3%),8例进展(13.3%)。在鼻咽癌患者中,有6例完全缓解(28.6%),9例部分缓解(42.8%),3例病情稳定(14.3%),3例进展(14.3%)。鳞状细胞癌组有5/60例患者(8.3%)无病生存期>18个月,鼻咽癌组有2/21例患者(9%)无病生存期>18个月。所有长期生存患者均具有以下特征:良好的身体状况(ECOG评分为0 - 1),首次治疗后的无病间期>12个月,局部非大块复发(rT1 - 2)。3/7例患者接受了姑息剂量(20 - 48Gy)的再照射。这种治疗可能在反应的持续时间和质量方面改善了对药物的反应。